Results of a small phase II trial presented at the 2013 ACC Scientific Sessions and published simultaneously in the Journal of the American College of Cardiology have been received with cautious enthusiasm. In this early study, 322 patients with non-ST-segment elevation myocardial infarction received a preprocedural infusion of inclacumab—a recombinant monoclonal antibody against P-selectin—or placebo before undergoing percutaneous coronary intervention (PCI). Markers of myocardial damage were assessed at intervals after PCI. Compared with placebo, inclacumab 20 mg/kg was associated with a marginally significant (P = 0.05) reduction in troponin I levels and a trend (P = 0.06) towards a reduction in CK-MB levels 24 h after PCI, but was not associated with significantly different rates of adverse events. No effect was seen for the 5 mg/kg dose of inclacumab.
ORIGINAL RESEARCH PAPER
Tardif, J. C. et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2013.03.003
Rights and permissions
About this article
Cite this article
Inclacumab might one day be SELECTed to reduce PCI-associated myocardial damage in patients with NSTEMI. Nat Rev Cardiol 10, 238 (2013). https://doi.org/10.1038/nrcardio.2013.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.40
